VivoSeq
Ophthalmology

Non-Proliferative Diabetic Retinopathy

21

Pipeline Programs↗

5

Active Trials↗

13

Companies Involved↗

Non-Proliferative Diabetic Retinopathy is an emerging landscape with 21 programs across 13 companies. The most active players are Bayer, EMD Serono, AstraZeneca. 5 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

15/100

Mech. Concentration

29/100

Completion Rate

50/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2A

Aerpio Therapeutics

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

19 of 24 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody313%Protein / enzyme28%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 92% of 26 pipeline programs.

Analysis

Trial Status

22

clinical trials

Unknown status7 · 32%
Completed5 · 23%
Terminated4 · 18%
Recruiting3 · 14%
Withdrawn1 · 5%
Active, not recruiting1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

22 trials

Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
Recruiting·BBeletalent (Zhuhai) Pharmaceutical Co., Ltd·Phase 3·NCT06817265·360 enrolled
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Recruiting·OOcular Therapeutix, Inc.·Phase 3·NCT07235085·930 enrolled
An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Recruiting·QQlaris Bio, Inc.·Phase 2·NCT07354477·14 enrolled
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
Active, not recruiting·SShanghai Eye Disease Prevention and Treatment Center·Phase 4·NCT06305143·58 enrolled
A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy
Not yet recruiting·SSichuan Academy of Medical Sciences·Phase 1·NCT07198815·10 enrolled
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
Completed·Bayer logoBayer·Phase 2·NCT04722991·109 enrolled
Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy
Completed·UUniversity of Guadalajara·Phase 2·NCT02062034·61 enrolled
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Completed·EEyePoint Pharmaceuticals, Inc.·Phase 2·NCT03197870·167 enrolled
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Completed·IInvirsa, Inc.·Phase 2·NCT06599684·19 enrolled
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
Completed·AAllegro Ophthalmics, LLC·Phase 2·NCT02435862·105 enrolled
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
Terminated·KKodiak Sciences Inc·Phase 3·NCT05066230·253 enrolled
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Terminated·Novartis logoNovartis·Phase 3·NCT00248131·260 enrolled
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Terminated·Novartis logoNovartis·Phase 3·NCT00248157·105 enrolled
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
Terminated·VVitreoretinal Technologies, Inc.·Phase 2/3·NCT00664183·400 enrolled
Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye
Withdrawn·UUniversity of Rochester·Phase 4·NCT04702048
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)